Clinical Trial Search

Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019

Primary: SCORAD Change Score — 33.34 Change Score

Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05

Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001

Primary: Percentage With Erythema on the Face at Baseline Before Investigational Product Application — 33.3; 71.9; 55.6; 6.3 Percentage of participants

Primary: Change From Baseline in the Itch Assessment Score Immediately Following Treatment — 1.93; 2.64 units on a scale — p=<0.001

Primary: Eczema Area and Severity Index (EASI) — 3.014; 3.359; 1.286; 1.621 units on a scale

Primary: Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50) — 37; 57; 61 percentage of participants — p==0.065

Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2

Primary: Number of Participants With Improved Skin Moisturization — 114 Participants

Primary: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 — -43.5; -62.0 Percent change from baseline

Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants

Primary: Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch) — 7.3; 7.26; 4.27; 4.6 score on a scale — p== 0.249

Primary: Change From Baseline in Three Item Severity Score — -2.6; -3.6 units on a scale

Primary: Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12. — -10.98; -25.99; -31.57 percent change — p=0.1308

Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants

Primary: Steroid Usage Quantity — 7.27; 10.78; 8.22 grams

Primary: Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score). — 131; 134; 37; 38 Participants

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…

Primary: Change in Epidermal Thickness — -31.66; -13.76; -28.65; -14.41 µm

Primary: Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Compared to the Control Area at End of Treatment — -1.9; -1.3 units on a…

Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…

Primary: Investigator Global Assessment of Improvement — 2; 2; 2 units on a scale

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.0 — 11 Participants

Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters

Primary: Safety Assessed by Adverse Events — 8.6; 7.8; 5.9; 4.9 percentage of participants

Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 32.0; 15.2 percentage of participants — p=<0.0001